We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study
Read MoreHide Full Article
Bristol-Myers Squibb Company (BMY - Free Report) announced updated data from the phase III CheckMate -651 study which is evaluating the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) compared to the EXTREME regimen (cetuximab, cisplatin/carboplatin and fluorouracil) as a first-line treatment in platinum-eligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck (“SCCHN”), a difficult-to-treat cancer.
Data from the same showed that treatment with the combo of Opdivo+Yervoy led to a clear, positive trend toward overall survival (“OS”) in patients whose tumors express PD-L1. However, the study did not meet its primary endpoints.
Shares of Bristol Myers have rallied 8.5% so far this year against the industry’s decrease of 2.8%.
Image Source: Zacks Investment Research
We remind investors that Opdivo as a monotherapy is currently approved for treating adult patients with recurrent/metastatic SCCHN after platinum-based therapy.
Per the company, the combination of Opdivo plus Yervoy has demonstrated significant improvements in OS in six late-stage studies evaluating the same across five different tumors.
Opdivo is approved in several countries for various indications — unresectable or metastatic melanoma, metastatic non-small-cell lung carcinoma (“NSCLC”) with progression on or after platinum-based chemotherapy, metastatic small cell lung cancer with progression after platinum-based chemotherapy, advanced renal cell carcinoma (“RCC”), adult patients with classical Hodgkin lymphoma (cHL), and recurrent or metastatic squamous cell carcinoma of the head and the neck, among others.
It is also approved for various indications in combination with Yervoy, like metastatic melanoma, NSCLC, malignant pleural mesothelioma and RCC, among others. The company continues to evaluate Opdivo alone or in combination therapies with Yervoy and other anti-cancer agents.
Approval of additional indications should boost Opdivo sales, which were not impressive in the first quarter of 2021. Notably, the drug faces stiff competition from Merck’s (MRK - Free Report) Keytruda and Roche’s (RHHBY - Free Report) Tecentriq.
Repligen’s earnings estimates have been revised 2.3% upward for 2021 and 1.2% upward for 2022 over the past 60 days. The stock has increased 4.5% year to date.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study
Bristol-Myers Squibb Company (BMY - Free Report) announced updated data from the phase III CheckMate -651 study which is evaluating the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) compared to the EXTREME regimen (cetuximab, cisplatin/carboplatin and fluorouracil) as a first-line treatment in platinum-eligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck (“SCCHN”), a difficult-to-treat cancer.
Data from the same showed that treatment with the combo of Opdivo+Yervoy led to a clear, positive trend toward overall survival (“OS”) in patients whose tumors express PD-L1. However, the study did not meet its primary endpoints.
Shares of Bristol Myers have rallied 8.5% so far this year against the industry’s decrease of 2.8%.
Image Source: Zacks Investment Research
We remind investors that Opdivo as a monotherapy is currently approved for treating adult patients with recurrent/metastatic SCCHN after platinum-based therapy.
Per the company, the combination of Opdivo plus Yervoy has demonstrated significant improvements in OS in six late-stage studies evaluating the same across five different tumors.
Opdivo is approved in several countries for various indications — unresectable or metastatic melanoma, metastatic non-small-cell lung carcinoma (“NSCLC”) with progression on or after platinum-based chemotherapy, metastatic small cell lung cancer with progression after platinum-based chemotherapy, advanced renal cell carcinoma (“RCC”), adult patients with classical Hodgkin lymphoma (cHL), and recurrent or metastatic squamous cell carcinoma of the head and the neck, among others.
It is also approved for various indications in combination with Yervoy, like metastatic melanoma, NSCLC, malignant pleural mesothelioma and RCC, among others. The company continues to evaluate Opdivo alone or in combination therapies with Yervoy and other anti-cancer agents.
Approval of additional indications should boost Opdivo sales, which were not impressive in the first quarter of 2021. Notably, the drug faces stiff competition from Merck’s (MRK - Free Report) Keytruda and Roche’s (RHHBY - Free Report) Tecentriq.
Zacks Rank & Stock to Consider
Bristol Myers currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Repligen Corporation (RGEN - Free Report) , which sports a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Repligen’s earnings estimates have been revised 2.3% upward for 2021 and 1.2% upward for 2022 over the past 60 days. The stock has increased 4.5% year to date.